findmyKOL

Sarah Wang, MD

Basic profile

Hematology / Oncology

ORCIDNone on fileNPI
RegionTyler, TX · South CentralSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Sarah Wang is an Oncology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
60companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

501 Saunders Ave Ste 300
Tyler, TX 757027524

Telephone

903-579-9800

Provider last certified this registry record 22 Jan 2024.

View the NPPES registry record

Industry payments

60 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    56.7%
    PD-1 inhibitor19.5%
    Pembrolizumab100%
    Part B, office-administered38 patients
    Platinum-based Drug15.8%
    Oxaliplatin98%Carboplatin2%
    Part B, office-administered24 patients

    + 9 more classes in this area

  • Blood & clotting

    18.1%
    Parenteral Iron Replacement11%
    Iron sucrose100%
    Part B, office-administered26 patients
    Erythropoiesis-stimulating Agent7.1%
    Darbepoetin alfa100%
    Part B, office-administered16 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    14.1%
    Other antiemetics10.5%
    Fosaprepitant100%
    Part B, office-administered35 patients
    Serotonin-3 Receptor Antagonist2.2%
    Palonosetron hcl52%Granisetron hydrochloride45%Ondansetron Hcl2%Ondansetron Odt1%
    Part D + Part B<11 patients

    + 6 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”